Our commitment to longevity research

Submit interest
AgelessRx Observational Initiative
Active, Recruiting Participants

AgelessRx Observational Initiative

Observed Changes in Various Longevity Monitoring Tools in Patients on Diverse Interventions

We would like to investigate GLP-1 Inhibitor products for efficacy as longevity and healthspan promoting products. These measures include measures of weight loss, mood, activity, alertness, cognitive function, fatigue, inflammation, immune health, and clinical and blood-based evaluations of health and longevity.

Completed

Rapamycin Trial

Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL)

Rapamycin is an FDA-approved antifungal agent, most used to prevent organ transplant rejection. Rapamycin targets the mTOR signaling pathway, which is associated with many aging-related diseases.

PEARL is a double-blind, randomized, placebo-controlled trial. Notably, it is the first nationwide telemedicine trial and the first large-scale intervention trial on longevity. PEARL is proudly sponsored by AgelessRx and affiliated with the University of California.

View publication
Rapamycin Trial
Post-COVID-19 Trial
Completed

Post-COVID-19 Trial

Pilot Study into Low Dose Naltrexone (LDN) and NAD+ for Treatment of Patients with Post-COVID-19 Syndrome

Proudly sponsored by AgelessRx, this double-blind placebo-controlled pilot study will assess the use of Low Dose Naltrexone (LDN) and NAD+ for the treatment of patients with post-COVID-19 syndrome (long-COVID-19).

AgelessRx will enroll over 60 people (must have had a positive test for SARS-CoV-2 1-4 months before enrollment) for a 12-week study. Patients will receive LDN and NAD+ treatment or a corresponding placebo tablet and patch (control group) for the 12-week duration.

View publication